Core Points - The Chinese government has included the human papillomavirus (HPV) vaccine in the national immunization program [3] - Girls born after November 10, 2011, who are 13 years old or older, can receive two doses of the bivalent HPV vaccine for free [2][3] - The bivalent HPV vaccine targets the 16 and 18 genotypes of the virus and is administered with a six-month interval between doses [3] Summary by Category - **Government Policy** - The inclusion of the HPV vaccine in the national immunization program is approved by the State Council [3] - **Target Population** - The program specifically targets girls who were born after November 10, 2011, and are at least 13 years old [2][3] - **Vaccine Details** - The vaccine provided is a bivalent type, focusing on genotypes 16 and 18, with a recommended administration schedule of two doses spaced six months apart [3]

Group 1 - The core viewpoint is that the HPV vaccine has been included in the national immunization program in China, allowing for free vaccination for eligible girls [4] - The vaccine is specifically targeted at girls born after November 10, 2011, who are 13 years old or older, and they can receive two doses of the bivalent HPV vaccine for free [2][4] - The vaccination will cover the HPV types 16 and 18, which are known to be associated with cervical cancer [4] Group 2 - The vaccination will be administered in two doses with a six-month interval between them [4] - This initiative is part of the government's efforts to enhance public health and prevent HPV-related diseases [4]

Core Viewpoint - The inclusion of the HPV vaccine in the national immunization program represents a significant commitment to women's health in China, aiming to reduce the burden of cervical cancer and promote public health [4][7]. Group 1: HPV Vaccine Implementation - The HPV vaccine will be available for free to girls who turn 13 years old after November 10, 2011, starting from November 10, 2025, with a total of two doses administered six months apart [4]. - In 2022, there were approximately 151,000 new cases of cervical cancer and about 56,000 deaths in China, highlighting the urgent need for preventive measures [4]. - The initiative aims to improve vaccination rates and reduce disparities in access among different regions and income groups, ensuring equitable health services for the target population [4][6]. Group 2: Immunization Effectiveness - Vaccinating girls at the age of 13 is expected to yield higher antibody levels and more durable protection against HPV [5]. - The decision to target 13-year-old girls for free vaccination is based on considerations of effectiveness, cost-benefit, and operational feasibility [4]. Group 3: Vaccine Production and Capacity - The domestic production of the bivalent HPV vaccine is handled by two companies, with an annual production capacity of 55 million doses, sufficient to meet market demand [6]. - All vaccines produced have received pre-certification from the World Health Organization, ensuring their quality and safety [6]. Group 4: Broader Health Impact - The inclusion of the HPV vaccine in the national immunization program marks a new phase in China's immunization efforts, contributing to global health equity [7]. - The initiative involves collaboration across multiple departments to ensure smooth implementation and effective monitoring of vaccination and associated risks [7].

Core Viewpoint - The inclusion of the HPV vaccine in the national immunization program is a significant step towards reducing cervical cancer incidence in China, but challenges remain in achieving effective vaccination rates and addressing existing immunity gaps among older populations [1][2]. Group 1: HPV Vaccine Implementation - The HPV vaccine will be provided for free to girls aged 13 and above, starting from November 10, 2025, as part of the national immunization program [1]. - The vaccination plan aims to ensure that girls receive two doses of the bivalent HPV vaccine, spaced six months apart, to establish immunity before potential sexual exposure [1][3]. - Previous initiatives in 18 provinces have shown that actual vaccination rates are not ideal, with school-based vaccination being a critical bottleneck [1][2]. Group 2: Target Population and Age Considerations - The decision to target girls aged 13 aligns with research indicating that vaccination between the ages of 9-14 generates a stronger immune response [3][4]. - There is a significant immunity gap among older populations who may not yet be eligible for cancer screenings, highlighting the need for ongoing vaccination efforts [2][10]. Group 3: Challenges in Implementation - The feasibility of mobilizing parents for vaccination in higher grades of elementary school is questioned, suggesting that early middle school is a more suitable time for vaccination [4][5]. - The notification includes provisions for catch-up vaccinations for girls who miss the initial opportunity, allowing for one additional dose before the age of 18 [8][10]. Group 4: Vaccine Market Dynamics - The government procurement price for the bivalent HPV vaccine is set at approximately 27.5 yuan per dose, with a total budget of about 425 million yuan for 2025 [14]. - The market for the HPV vaccine is expected to stabilize in terms of pricing, as the focus shifts from price competition to ensuring vaccine quality [15][17]. Group 5: Integration of Preventive Measures - The integration of HPV vaccination with cervical cancer screening is seen as a cost-effective strategy to reduce overall healthcare expenditures related to cervical cancer treatment [13]. - The potential for optimizing screening strategies in the "post-vaccine era" is highlighted, with suggestions for extending screening intervals as vaccination rates increase [13].

Core Viewpoint - The Chinese government has announced the inclusion of the HPV vaccine in the national immunization program, providing free vaccinations for girls born after November 10, 2011, starting from November 10, 2025 [1] Group 1 - The announcement was made by seven ministries, including the National Health Commission and the Ministry of Education [1] - The program will offer two doses of the bivalent HPV vaccine, with a six-month interval between doses [1] - The China Center for Disease Control and Prevention will be responsible for gathering vaccine demand information and conducting centralized procurement [1]

经国务院同意，我国在现行国家免疫规划疫苗基础上，将人乳头瘤病毒(HPV)疫苗纳入国家免疫规划， 为2011年11月10日以后出生的满13周岁女孩，免费接种2剂次针对16和18基因型病毒的双价HPV疫苗(间 隔6个月)。 (责任编辑：朱赫) ...

Core Points - The Chinese government has included the HPV vaccine in the national immunization program, offering free vaccinations to girls born after November 10, 2011, starting from November 10, 2025 [1][2] - The target demographic for the HPV vaccination is girls aged 13, aligning with WHO recommendations for girls aged 9-14 who have not engaged in sexual activity [1][2] - The HPV vaccine has been proven safe and effective in China, with sufficient production capacity to meet demand, and the initiative aims to provide two doses of the bivalent HPV vaccine for free [1] Health Context - Cervical cancer is a common malignancy among women in China, with increasing incidence and mortality rates, particularly among younger women [2] - The WHO's global strategy aims for 90% of girls under 15 to be vaccinated by 2030, and China's action plan (2023-2030) promotes HPV vaccination and pilot programs in resource-limited areas [2] - Eighteen provinces in China have already implemented policies for free HPV vaccinations or subsidies for eligible girls, laying a practical foundation for the national program [2]

Core Viewpoint - The Chinese government has officially included the HPV vaccine in the national immunization program, initiating centralized procurement for the bivalent HPV vaccine, with a total procurement quantity of 15.4465 million doses and a budget of approximately 425 million yuan [1][3]. Group 1: Procurement Details - The centralized procurement for the bivalent HPV vaccine is set for October to December 2025, with a unit price of approximately 27.5 yuan per dose, which is expected to cover 7.72325 million girls aged 9 to 14 years [1][2]. - The procurement is managed by the Chinese Center for Disease Control and Prevention, with a total budget of 424.78 million yuan [2]. Group 2: Market Analysis - The market for the bivalent HPV vaccine consists of two segments: the existing market for girls aged 9 to 14 and the annual new entrants into this age group [5]. - From 2025 to 2030, the female population aged 9 to 14 is projected to be approximately 48.9 million to 43.7 million, with a cumulative incremental market size estimated at around 1.6 billion yuan [5][6]. - The total market size for the national immunization program from 2025 to 2030 is expected to be around 3.8 billion yuan, considering both the existing and incremental markets [8][9]. Group 3: Competitive Landscape - A price war has emerged between Watson Bio and Wantai Bio over the bivalent HPV vaccine, with the winning bid price dropping from an initial range of 329 to 344 yuan per dose to the current price of 27.5 yuan [9][10]. - The competitive dynamics shifted significantly after the National Health Commission announced plans to promote free HPV vaccinations, leading to rapid market expansion [9]. - Wantai Bio has engaged in aggressive pricing strategies, with bids as low as 63 yuan per dose in 2024, indicating a continued trend of price reductions in the market [10].

Group 1 - The core viewpoint of the article highlights the inclusion of the HPV vaccine in China's national immunization program, indicating a significant step in public health policy [1] - The announcement of the centralized procurement project for the bivalent human papillomavirus vaccine has a budget of approximately 425 million yuan, with a total quantity of 15.4465 million doses [1] - The maximum price per dose is set at no more than 27.5 yuan, which reflects the government's effort to make the vaccine more accessible [1]

Core Viewpoint - China will include HPV (Human Papillomavirus) vaccines in its national immunization program this year, aiming to accelerate the global goal of eliminating cervical cancer by 2030 through vaccination initiatives targeted at eligible women [1] Group 1 - The National Health Commission of China announced the integration of HPV vaccines into the national immunization plan [1] - Multiple vaccination services for eligible women will be launched as part of this initiative [1] - China plans to make a concerted effort towards the World Health Organization's 2030 vaccination phase goal for the global strategy to eliminate cervical cancer [1]